In addition to considering the possible applications/ repurposing of anti-inflammatory agents for mood disorders, preliminary results suggest that inflammatory biomarkers/ biosignatures may offer some predictive information as to response to conventional antidepressants. For example, a recently published study utilizing a post-hoc methodology concluded that baseline HRCSP levels may identify individuals preferentially response to SSRIs or serotonin and norepinephrine inhibitors.17

It should not be forgotten that non-pharmacological approaches, such as mindfulness-based therapy, aerobic exercise, dietary modification, sleep/ chronobiological normalization as well as a healthier lifestyle may also exert beneficial influences on immunoinflammatory functioning, providing further impetus for integrative approaches to disease modelling and treatment.18

Continue Reading

In conclusion, disturbances in the neuroinflammatory system are implicated and empirically supported by both clinical and preclinical evidence to be relevant to the pathogenesis and possibly treatment of mood and other brain disorders. Research vistas for the future are to refine markers across brain illnesses with consideration given to symptomatic status and phase in illness trajectory.

Although beyond the available data, it is reasonable for clinicians to encourage patients to reduce the risk for “inflammatory-based” medical morbidity, e.g. overweight/obesity and to engage in broad-based therapeutic endeavours in lifestyle changes that would exert a favourable influence on their inflammatory system.

Roger McIntyre, MD, is head of the Mood Disorders Psychopharmacology Unit at the University Health Network, in Toronto, Canada. He is also a member of the Psychiatry Advisor editorial board.


  1. McIntyre RS. A Vision for Drug Discovery and Development: Novel Targets and Multilateral Partnerships. Adv Ther. 2014; 31(3): 245-246.
  2. Nierenberg AA and DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001; (62) Suppl 16:5-9.
  3. Soczynska JK, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med. 2011;13(2):93-116.
  4. Raison CL, et al. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24-31.
  5. Miller AH,et al. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009; 65(9):732-41.
  6. Raison CL, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013; 70(1):31-41.
  7. McIntyre RS, et al. Advancing biomarker research: utilizing ‘Big Data’ approaches for the characterization and prevention of bipolar disorder. Bipolar Disord. 2014; 16(5): 531-547.
  8. Noto C, et al. Targeting the inflammatory pathway as a therapeutic tool for major depression. Neuroimmunomodulation. 2014; 21(2-3):131-9.
  9. Wilson CJ, et al. Cytokines and cognition–the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc. 2002;50(12):2041-56.
  10. Schram MT, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc. 2007; 55(5):708-16.
  11. Harrison NA, et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry. 2009; 66(5):407-14.
  12. Haroon E, et al. IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology. 2014; (7):1777-85.
  13. Old LJ. Tumor necrosis factor (TNF). Science. 1985; 230(4726):630-2.
  14. Musselman DL, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344(13):961-6.
  15. Asnis GM, et al. Interferon-induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):808-18.
  16. Kohler O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014;71(12):1381-91.
  17. Uher R, et al. An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline. Am J Psychiatry. 2014 ; 171(12):1278-1286.
  18. Okun ML, et al. Sleep variability, health-related practices, and inflammatory markers in a community dwelling sample of older adults. Psychosom Med. 2011;73(2):142-50.